Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Clinical Trials of Cancer Immunotherapies

Abstract A019: Longitudinal analysis of the landscape of cancer trials testing anti-PD-1/L1 monoclonal antibodies

Jun Tang, Laura Pearce, Jill O'Donnell-Tormey and Vanessa M. Hubbard-Lucey
Jun Tang
Cancer Research Institute, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Pearce
Cancer Research Institute, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jill O'Donnell-Tormey
Cancer Research Institute, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanessa M. Hubbard-Lucey
Cancer Research Institute, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A019 Published February 2019
  • Article
  • Info & Metrics
Loading
Abstracts: Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 30 - October 3, 2018; New York, NY

Abstract

Background: Monoclonal antibodies targeting PD-1 or PD-L1 (PDx) have revolutionized the standards of care for many types of cancer. As of June 2018, 5 anti-PDx agents have been approved by the FDA as monotherapy or part of combination therapy to treat 13 different cancer types. Since the first anti-PDx trial started in 2006, the anti-PDx clinical trial landscape has dramatically evolved. A current understanding of this expanding landscape by stakeholders in the immunotherapy clinical development enterprise will help to inform their prioritization of clinical trials and to support more efficient and effective evaluation of promising treatments. Methods: The Cancer Research Institute, a leading nonprofit organization dedicated to cancer immunotherapy research, has been tracking the progress in the immuno-oncology space over the past 5 years. Having analyzed the database at Clinicaltrials.gov, we were able to compare the available information regarding new interventional cancer trials evaluating PDx with that of all interventional cancer trials. We also compared the current PDx trial landscape with our previous PDx trial analysis conducted in Sept. 2017. Results: In the past decade, the new interventional cancer trials started per year have gradually increased from 2,294 in 2008 to 3,727 in 2017. However, during the same period of time, the number of new PDx trials per year increased from one in 2008 to 776 in 2017. Significantly, PDx trials accounted for 21% of all new interventional cancer trials in 2017. While the number of new trials increased, the average planned patient enrollment per PDx trial decreased from 476 patients in 2011 to 132 patients in 2017. When compared with our previous landscape analysis conducted in Sept. 2017, we found the number of active PDx trials (including both monotherapy and combination) increased from 1,502 as of Sept. 2017 to 2,011 as of Jun 2018, and the number of active PDx combination trials increased from 1,105 to 1,449 during the same time. Finally, in addition to PD-1 or PD-L1, other cancer targets evaluated by those PDx combination trials have expanded from 166 as of Sept. 2017 to 266 as of June 2018, and the planned patient enrollment of these combination trials expanded from 165,215 to 225,747 accordingly. Conclusion: Our landscape analyses show that the PDx trial space has been rapidly expanding, and the numbers of new trials started per year suggest no indication of slowing down in the near future. The 2,011 ongoing PDx trials are a testament to the field’s commitment to developing more effective immunotherapies that will build on the success of PDx checkpoint inhibitors. Care should be given, however, to ensure the trials being conducted are testing new PDx therapies or expanding the effectiveness of PDx therapies to new cancer types while avoiding the concentration of trials testing similar PDx therapies in a few identical cancer conditions.

Citation Format: Jun Tang, Laura Pearce, Jill O'Donnell-Tormey, Vanessa M. Hubbard-Lucey. Longitudinal analysis of the landscape of cancer trials testing anti-PD-1/L1 monoclonal antibodies [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A019.

  • ©2019 American Association for Cancer Research.
Previous
Back to top
Cancer Immunology Research: 7 (2 Supplement)
February 2019
Volume 7, Issue 2 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A019: Longitudinal analysis of the landscape of cancer trials testing anti-PD-1/L1 monoclonal antibodies
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A019: Longitudinal analysis of the landscape of cancer trials testing anti-PD-1/L1 monoclonal antibodies
Jun Tang, Laura Pearce, Jill O'Donnell-Tormey and Vanessa M. Hubbard-Lucey
Cancer Immunol Res February 1 2019 (7) (2 Supplement) A019; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A019: Longitudinal analysis of the landscape of cancer trials testing anti-PD-1/L1 monoclonal antibodies
Jun Tang, Laura Pearce, Jill O'Donnell-Tormey and Vanessa M. Hubbard-Lucey
Cancer Immunol Res February 1 2019 (7) (2 Supplement) A019; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A019
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Clinical Trials of Cancer Immunotherapies

  • Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma
  • Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading
  • Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Show more Clinical Trials of Cancer Immunotherapies

Clinical Trials of Cancer Immunotherapies: Poster Presentations - Proffered Abstracts

  • Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma
  • Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading
  • Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Show more Clinical Trials of Cancer Immunotherapies: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement